<DOC>
	<DOCNO>NCT00464542</DOCNO>
	<brief_summary>An important contributor epidemic spread herpes simplex virus type 2 ( HSV-2 ) high frequency asymptomatic shed genital tract , transmission usually occur period subclinical reactivation virus ( 1 ) . Therefore , improve understanding risk factor associate HSV-2 shed need . The researcher ' preliminary data suggest bacterial vaginosis ( BV ) may associate increase genital tract shed HSV-2 ( 2 ) . As BV common cause vaginal symptom reproductive age woman , even modest association genital tract shed HSV-2 would result substantial attributable risk transmission virus . The researcher ' investigation ass effect asymptomatic BV daily genital tract shed HSV-2 determine shed frequency treatment asymptomatic BV . To , researcher enroll 35 HSV-2 seropositive woman asymptomatic BV . These woman instruct self-collect daily swab specimens HSV-2 deoxyribonucleic acid ( DNA ) polymerase chain reaction ( PCR ) analysis low genital tract one month . At end one month follow-up visit , participant complete one week course oral metronidazole treatment BV . This follow daily home collection genital tract swab specimens additional one month .</brief_summary>
	<brief_title>Asymptomatic Bacterial Vaginosis Herpes Simplex Virus Type 2 ( BV/HSV-2 ) Shedding Study</brief_title>
	<detailed_description />
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis , Bacterial</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Women 1826 year old age Only woman deny symptom vaginal discharge odor meet Amsel Gram stain criterion diagnosis BV eligible Amsel criterion ( 3 follow 4 condition ) ( 10 ) : Homogenous vaginal discharge Vaginal pH &gt; 4.5 Positive amine ( sniff ) test Presence clue cell vaginal fluid Gram stain criterion ( 11 ) : Score : 03 ; classification : normal ; vaginal bacteria morphotype : Lactobacillus predominant Score : 46 ; classification : intermediate ; vaginal bacteria morphotype : Lactobacilli reduce Score : 710 ; classification : BV ; vaginal bacteria morphotype : Lactobacillus replace Gardnerella anaerobe It report 50 % woman meet clinical criterion BV deny symptom ( 12 ) . In addition , routine antimicrobial treatment woman asymptomatic BV currently recommend Centers Disease Control ( 13 ) . Eligible woman need test positive HSV2 typespecific antibody . Determination HSV2 serostatus determine point care typespecific immunoassay kit ( biokit HSV2 Rapid Test , biokit USA ) . Patients capable provide write informed consent Patients willing refrain use intravaginal product ( i.e. , contraceptive cream , gel , foam , sponge , lubricant , douche , etc . ) study period Patients willing refrain use systemic topical genital antiviral medication study period Patients willing capable cooperate extent degree require protocol HSV2 seronegativity ( determine POC immunoassay ) Pregnancy ( woman receive pregnancy test prior enrollment ) woman currently practice effective method birth control Current Chlamydia trachomatis , Neisseria gonorrhea , Trichomonas vaginalis infection Use prescriptive antiviral treatment presume HSV reactivation within 14 day prior enrollment Use systemic antimicrobial within past 14 day History hypersensitivity inability tolerate systemic metronidazole therapy Nursing mother Patients intrauterine device Unwillingness refrain initiation antiviral medication study period Unwillingness refrain use douche product study period Unwillingness refrain ingestion alcoholic beverage oneweek course oral metronidazole therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>26 Years</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>herpes simplex virus</keyword>
</DOC>